Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Oncolytics Biotech Inc.NASDAQ: ONCY

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items turns positive

Q1 FY2026 other non-cash items was CA$1.14M, compared with -CA$262K a year earlier. Trailing-twelve-month other non-cash items was -CA$4.88M.

Context

  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near CA$1.14M or moves back toward the trailing-twelve-month quarterly average of -CA$1.22M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$1.14M+115.7% QoQ
Last fiscal yearDec 2025
CA$5.89M+403.5% YoY
LTMMar 2026
-CA$4.88M+407.6% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+534.3%——
1 year+403.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

CAD · from the cash flow

Latest · FY2025
5.89M CAD
Year-over-year change
+403.5%
4-year CAGR
+183.1%

Other Non-Cash Items vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +407.6% is the 4th highest of 8, against a peer median of -35.9%.
ONCY Competitors
Other Non-Cash Items for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$304.73M USD+538.7%—4066.4%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$86.33M USD+713.4%—1208.3%
CLNNClene Inc.LTM Mar 2026$12.53M USD+5079.4%—9353.8%
TILInstil Bio, Inc.LTM Mar 2026$11.87M USD-50.5%+17.3%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$4.88M CAD+407.6%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$4.69M USD-173.0%——
COYACoya Therapeutics, Inc.LTM Mar 2026$2.3M USD—-17.1%29.0%
MGNXMacroGenics, Inc.LTM Mar 2026$1.21M USD-96.9%-31.8%0.8%
IMMXImmix Biopharma, Inc.LTM Mar 2026$1.03M USD-35.9%——
Peer median (excluding ONCY) —-35.9%-17.1%1208.3%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.3M)(24.84M)(27.75M)(31.71M)(39.46M)
Depreciation & Amortization452.07K392K403K424K96.05K
Deferred Income Tax408.56K0000
Stock-Based Compensation3.83M2.38M2.07M2.72M4.26M
Change in Working Capital(907.99K)391K1.77M3.54M1.62M
Accounts Receivables(776.39K)345K506K(53K)4.03M
Inventory00000
Accounts Payables00000
Other Working Capital(131.59K)46K1.26M3.59M(2.41M)
Other Non-Cash Items91.73K(1.68M)(4.93M)(1.94M)5.89M
Operating Cash Flow(22.43M)(23.36M)(28.45M)(26.97M)(27.6M)
Capital Expenditures(285.95K)(55K)(8K)(239K)(8.23K)
Acquisitions (Net)00000
Purchases of Investments0(20.35M)000
Sales of Investments0020.23M00
Other Investing Activities0(20.35K)000
Investing Cash Flow(285.95K)(20.4M)20.22M(239K)(8.23K)
Debt Repayment(366K)(381K)(407K)(348K)0
Common Stock Issued32.91M12.57M31.62M6.92M19.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities469.68K12K781K65K(37.05K)
Financing Cash Flow33.02M12.21M31.99M6.64M19.37M
Effect of Forex Changes(253.25K)1.96M(522K)1.6M166.03K
Net Change in Cash10.04M(29.6M)23.25M(18.97M)(8.06M)
Free Cash Flow(22.72M)(23.41M)(28.46M)(27.21M)(27.6M)

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.